Hogy Medical Co.,Ltd.
Stock Price Chart
2026/03/02 UpdatedPrice Trend
2026/03/02 UpdatedPrice & Trading Details
2026/03/02 UpdatedPRICE
TRADING
Analyst Recommendations 3 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Major Holders
Updated 2026/03/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
250.8K | +6.09% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
159.2K | +4.05% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
140.3K | 0.00% | |
|
GMO TRUST-GMO Implementation Fund
|
137.4K | 0.00% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
76.4K | 0.00% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
|
68.8K | -11.57% |
Dividend History
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥68 | -15.6% |
| 2024 | ¥80 | +2.6% |
| 2023 | ¥78 | +11.4% |
| 2022 | ¥70 | +2.9% |
| 2021 | ¥68 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥36,778M | ¥38,981M | ¥39,100M | ¥39,138M |
| Gross Profit | ¥15,416M | ¥15,740M | ¥13,063M | ¥12,621M |
| Operating Income | ¥6,135M | ¥6,635M | ¥4,169M | ¥3,811M |
| Pretax Income | ¥6,292M | ¥6,218M | ¥4,098M | ¥3,004M |
| Net Income | ¥4,370M | ¥4,316M | ¥2,804M | ¥1,520M |
| EPS | ¥153.00 | ¥177.95 | ¥115.57 | - |
| Operating Margin | 16.68% | 17.02% | 10.66% | 9.74% |
| Balance Sheet | ||||
| Total Assets | ¥98,967M | ¥102,180M | ¥100,041M | ¥97,895M |
| Total Equity | ¥79,957M | ¥83,606M | ¥86,110M | ¥74,323M |
| Total Liabilities | ¥19,010M | ¥18,574M | ¥13,931M | ¥23,572M |
| Cash | ¥14,364M | ¥18,862M | ¥19,419M | ¥22,005M |
| Interest-bearing Debt | ¥10,003M | ¥8,890M | ¥5,823M | ¥13,789M |
| Equity Ratio | 80.79% | 81.82% | 86.07% | 75.92% |
| D/E Ratio | 0.13 | 0.11 | 0.07 | 0.19 |
| Cash Flow | ||||
| Operating CF | ¥8,501M | ¥9,176M | ¥7,117M | ¥11,555M |
| Investing CF | -¥3,812M | -¥1,951M | -¥3,262M | -¥3,917M |
| Financing CF | -¥11,049M | -¥3,142M | -¥3,892M | -¥5,455M |
| Free CF | ¥5,300M | ¥7,784M | ¥4,316M | ¥6,248M |
| Efficiency | ||||
| ROE | 5.47% | 5.16% | 3.26% | 2.05% |
| ROA | 4.42% | 4.22% | 2.80% | 1.55% |
Latest IR Information
-
Notice of Setting the Record Date for the Extraordinary General Meeting of Shareholders
The record date for the extraordinary general meeting of shareholders is set as March 18, 2026. This measure is taken in preparation for the privatization procedure following the successful tender offer by TCG2509 Co., Ltd. for our shares.
Read more -
(Amendment) Notice Regarding Changes to the Expression of Opinion in Support and Recommendation to Apply for the Tender Offer by TCG2509 Co., Ltd. for Shares of the Company
TCG2509 Co., Ltd. has extended the tender offer period for shares of Hogi Medical Co., Ltd. from February 5, 2026, to 40 business days (until February 20, 2026) and changed the settlement start date to March 2, 2026.
Read more -
(Correction) Notice Regarding Correction of "Announcement of Commencement of Tender Offer for Common Shares of Hogi Medical Co., Ltd. (Securities Code: 3593) by TCG2509 Co., Ltd."
The tender offer period by TCG2509 Co., Ltd. for shares of Hogi Medical Co., Ltd. has been extended to 40 business days from February 5, 2026, and the settlement start date has also been postponed to March 2, 2026.
Read more -
Financial Summary for the Third Quarter of Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated)
For the third quarter of the fiscal year ending March 2026, net sales amounted to 28,719 million yen (4.3% decrease year-over-year), operating income was 2,088 million yen (38.7% decrease year-over-year), and quarterly net income attributable to owners of the parent...
Read more -
Fiscal Year Ending March 2026 Q3 Financial Results Presentation
For the cumulative third quarter of the fiscal year ending March 2026, net sales were JPY 28.71 billion (95.7% YoY), operating income was JPY 2.08 billion (61.3% YoY), and net income attributable to owners of parent was JPY 1.43 billion...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥4,400
Rating Score: 3.00 (Based on 3 analysts)
※1=Strong Buy, 5=Strong Sell
Hogy Medical Extends Tender Offer Timeline After Regulatory Waiting Period Shortened - TipRanks ↗
Company Information
About
Hogy Medical Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of medical consumables, medical equipment, and medical nonwoven products in Japan. The company offers surgical kit products; sterilization products comprising Mekkin bags sterilization pouches and sterilization containers; non-woven fabric products; remanufactured single-use devices; operation support related, such as operating room management services, OPENO, case studies services, and OPERA-Compass and narcotics and poisons box. It also provides minimally invasive treatment products, including SuReFInD for assistance in the excision of small-cell lung cancer in pneumonectomy operations; EMARO, an endoscope holder; SECUREA, a sponge for endoscopic surgery; and personal protective equipment related products. The company was formerly known as Hogy Co., Ltd. and changed its name to Hogy Medical Co.,Ltd. in 1987. Hogy Medical Co.,Ltd. was incorporated in 1961 and is headquartered in Tokyo, Japan.
